Lineage Cell Therapeutics Valuation Multiples

Lineage Cell Therapeutics Overview

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Founded

1990

HQ

Employees

77

Website

lineagecell.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $19M

EBITDA: ($32M)

EV

$373M

Valuation Multiples

Multiples.vc

Start free trial

Lineage Cell Therapeutics Financials

Lineage Cell Therapeutics reported last 12-month revenue of $19M and negative EBITDA of ($32M).

In the same LTM period, Lineage Cell Therapeutics generated $19M in gross profit, ($32M) in EBITDA losses, and had net loss of ($47M).

Lineage Cell Therapeutics P&L

In the most recent fiscal year, Lineage Cell Therapeutics reported revenue of $15M and EBITDA of ($21M).

Lineage Cell Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Lineage Cell Therapeutics Stock Performance

Lineage Cell Therapeutics has current market cap of $426M, and enterprise value of $373M.

Lineage Cell Therapeutics' stock price is $1.71.

Lineage Cell Therapeutics Valuation Multiples

Lineage Cell Therapeutics trades at 19.5x EV/Revenue multiple, and (11.6x) EV/EBITDA.

Lineage Cell Therapeutics Financial Valuation Multiples

As of April 18, 2026, Lineage Cell Therapeutics has market cap of $426M and EV of $373M.

Equity research analysts estimate Lineage Cell Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lineage Cell Therapeutics has a P/E ratio of (9.0x).

Lineage Cell Therapeutics Margins & Growth Rates

Lineage Cell Therapeutics' revenue in the last 12 month grew by 33%.

Lineage Cell Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Lineage Cell Therapeutics' rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lineage Cell Therapeutics' rule of X is 188% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Lineage Cell Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Lineage Cell Therapeutics M&A Activity

Lineage Cell Therapeutics acquired XXX companies to date.

Last acquisition by Lineage Cell Therapeutics was on XXXXXXXX, XXXXX. Lineage Cell Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Lineage Cell Therapeutics Investment Activity

Lineage Cell Therapeutics invested in XXX companies to date.

Lineage Cell Therapeutics made its latest investment on XXXXXXXX, XXXXX. Lineage Cell Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).